Effects of combination therapy with sitagliptin and metformin on glycemic control-related factor, beta-cell function, lipid profile, and kidney function in patients with type 2 diabetes.

Effects of combination therapy with sitagliptin and metformin on glycemic control-related factor, beta-cell function, lipid profile, and kidney function in patients with type 2 diabetes. - COAST study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013509

Enrollment

Registered

2014-03-26

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)HbA1c(JDS)6.1% was not achieved after treatment by life style intervention 2)over 20 years old patient 3)Given informed consent

Exclusion criteria

Exclusion criteria: 1) type 1 diabetes 2) had ketosis or coma within 6 month 3) after severe infection, operation or injure 4) impaired renal function (Serum Cr>1.5mg/dL for male,>1.3mg/dL for female) 5) is pregnancy or chance of pregnant 6) Under treatment by other anti-diabetic drugs 7) Has allergy to DPP-4 inhibitor 8) Patient who was considered to be appropriate to this study by attending physician

Design outcomes

Primary

Measure	Time frame
Change rate of HbA1c	—

Secondary

Measure	Time frame
Chage rate of fasting blood glucose, active GLP-1, proinsulin / insulin ratio (P / I), HOMA-beta, HOMA-R, general lipid, RLP-C, LPL, HPLC lipoprotein quantitative analysis (H) , urinary albumin (ACR), cystatin C, L-type fatty acid binding protein (L-FABP), liver function.	—

Countries

Japan

Contacts

Public ContactNobuichi Kuribayashi

Misaki naika clinic Misaki naika clinic

misakin@bh.wakwak.com047-440-2222

Outcome results